U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H20F3N5O2S2
Molecular Weight 519.562
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DABRAFENIB

SMILES

CC(C)(C)C1=NC(=C(S1)C2=NC(N)=NC=C2)C3=CC=CC(NS(=O)(=O)C4=C(F)C=CC=C4F)=C3F

InChI

InChIKey=BFSMGDJOXZAERB-UHFFFAOYSA-N
InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)

HIDE SMILES / InChI

Description

Dabrafenib is a selective, orally bioavailable inhibitor of Mutant BRAF protein kinase with potential antineoplastic activity. Dabrafenib inhibits BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2 and 5.0 nM. BRAF belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. Mutations in BRAF are associated with increased growth and proliferation of cancer cells. By inhibiting BRAF kinase dabrafenib negatively regulates the proliferation of tumor cells which contain a mutated BRAF gene. Dabrafenib (in combination with trametinib or alone) is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.2 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TAFINLAR

Cmax

ValueDoseCo-administeredAnalytePopulation
2497.4 ng/mL
300 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens
806 ng/mL
300 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens
1478 ng/mL
150 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
13485.6 ng × h/mL
300 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens
2619 ng × h/mL
300 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens
4341 μg × h/mL
150 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
4.9 h
300 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens
5.2 h
300 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens
8 h
150 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
0.3%
150 mg 2 times / day multiple, oral
DABRAFENIB plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dosage regimens are: 150 mg orally taken twice daily, approximately 12 hours apart, as a single agent or 150 mg orally taken twice daily, approximately 12 hours apart, in combination with trametinib 2 mg orally taken once daily.
Route of Administration: Oral
In Vitro Use Guide
A375, SK-MEL-28, WM239 and SK-MEL-5 cells with 2.5, 5 and 10 nM dabrafenib for 72 hours. Dabrafenib treatment induced massive Mcl-1 expression at all the three concentrations. The IC50 of dabrafenib in A375, SK-MEL-28 and WM-239 was 5nM, 2nM and 6nM respectively. In dabrafenib resistant A375, SK-MEL-28 and WM-239 cells, which were denoted as A375-DR, SK-MEL-28-DR and WM-239-DR that were incubated with up to 300 nM inhibitor concentrations the IC50s were greater than 100 nM indicating more than 30-fold resistance.